Doses up to 400 mg/day, given as a single dose, have been well tolerated, but there is no consistent evidence that this dose confers additional benefit beyond that of the 200 mg/day dose [see Clinical Pharmacology (12.3) and Clinical Studies (14.1, 14.2)].

**2.2 Dosage in Shift Work Disorder (SWD)**

- **Geriatric Patients**: consider lower dose. (2.4, 12.3)

The recommended dosage of PROVIGIL for each indication is as follows:

- **Narcolepsy or OSA**: 200 mg once a day in the morning. (2.1)

- **SWD**: 200 mg once a day, taken approximately one hour prior to start of the work shift. (2.2)

- **Severe Hepatic Impairment**: reduce dose to half the recommended dose. (2.3, 12.3)

DOSAGE FORMS AND STRENGTHS

Tablets: 100 mg and 200 mg. (3)

CONTRAINDICATIONS

PROVIGIL is contraindicated in patients with known hypersensitivity to modafinil or armodafinil. (4)

**5.3 Multi-organ Hypersensitivity Reactions**

- **Known Cardiovascular Disease**: Consider increased monitoring. (5.7)

In OSA, PROVIGIL is indicated to treat excessive sleepiness and not as treatment for the underlying obstruction.

**Dosage and Administration**

The recommended dosage of PROVIGIL for each indication is as follows:

- **Narcolepsy or OSA**: 200 mg once a day. (2.1)

- **SWD**: 200 mg once a day, taken approximately one hour prior to the start of their work shift. (2.2)

- **Severe Hepatic Impairment**: reduce dose to half the recommended dose. (2.3, 12.3)

- **Geriatric Patients**: consider lower dose. (2.4, 12.3)

**DOSAGE FORMS AND STRENGTHS**

Tablets: 100 mg and 200 mg. (3)

**CONTRAINDICATIONS**

PROVIGIL is contraindicated in patients with known hypersensitivity to modafinil or armodafinil. (4)

**8.5 Pediatric Use**

**9.2 Abuse**

**9.3 Dependence**

**10 OVERDOSAGE**

**11 DESCRIPTION**

**12 CLINICAL PHARMACOLOGY**

- **12.1 Mechanism of Action**

- **12.3 Pharmacokinetics**

**9 DRUG ABUSE AND DEPENDENCE**

- **9.1 Controlled Substance**

- **9.2 Abuse**

- **9.3 Dependence**

**16 HOW SUPPLIED/STORAGE AND HANDLING**

- **16.1 How Supplied**

- **16.2 Storage**

**17 PATIENT COUNSELING INFORMATION**

*Sections or subsections omitted from the full prescribing information are not listed.*

**REVISED: 01/2015**

**WARNINGS AND PRECAUTIONS**

- **Serious Rash, including Stevens-Johnson Syndrome**: Discontinue PROVIGIL at the first sign of rash, unless the rash is clearly not drug-related. (5.1)

- **Angioedema and Anaphylaxis Reactions**: If suspected, discontinue PROVIGIL. (5.2)

- **Multi-organ Hypersensitivity Reactions**: If suspected, discontinue PROVIGIL. (5.3)

- **Persistent Sleepiness**: Assess patients frequently for degree of sleepiness and, if appropriate, advise patients to avoid driving or engaging in any other potentially dangerous activity. (5.4)

- **Psychiatric Symptoms**: Use caution in patients with a history of psychosis, depression, or mania. Consider discontinuing PROVIGIL if psychiatric symptoms develop. (5.5)

- **Known Cardiovascular Disease**: Consider increased monitoring. (5.7)

**ADVERSE REACTIONS**

Most common adverse reactions (≥5%): headache, nausea, nervousness, rhinitis, diarrhea, back pain, anxiety, insomnia, dizziness, and dyspepsia. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Teva Pharmaceuticals at 1-888-483-8279 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

**DRUG INTERACTIONS**

- **Steroidal contraceptives (e.g., ethinyl estradiol)**: Use alternative or concomitant methods of contraception while taking PROVIGIL and for one month after discontinuation of PROVIGIL treatment. (7)

- **Cyclosporine**: Blood concentrations of cyclosporine may be reduced. (7)

- **CYP2C19 substrates**, such as omeprazole, phenytoin, and diazepam: Exposure of these medications may be increased. (7)

**USE IN SPECIFIC POPULATIONS**

Pregnancy: Based on animal data, may cause fetal harm. (8.1)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

**FULL PRESCRIBING INFORMATION: CONTENTS**

- **1 INDICATIONS AND USAGE**

- **2 DOSAGE AND ADMINISTRATION**

- **3 DOSAGE FORMS AND STRENGTHS**

- **4 CONTRAINDICATIONS**

- **5 WARNINGS AND PRECAUTIONS**

- **6 ADVERSE REACTIONS**

- **7 DRUG INTERACTIONS**

- **8 USE IN SPECIFIC POPULATIONS**

- **9 DRUG ABUSE AND DEPENDENCE**

- **10 OVERDOSAGE**

- **11 DESCRIPTION**

- **12 CLINICAL PHARMACOLOGY**

- **13 NONCLINICAL TOXICOLOGY**

- **14 CLINICAL STUDIES**

- **15 CLINICAL PHARMACOLOGY**

- **16 HOW SUPPLIED/STORAGE AND HANDLING**

- **17 PATIENT COUNSELING INFORMATION**

- **FULL PRESCRIBING INFORMATION**

- **1 INDICATIONS AND USAGE**

PROVIGIL is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD). (1)

**Limitations of Use**

In OSA, PROVIGIL is indicated to treat excessive sleepiness and not as treatment for the underlying obstruction.

- **Dosage and Administration**

  The recommended dosage of PROVIGIL for each indication is as follows:

  - **Narcolepsy or OSA**: 200 mg once a day. (2.1)

  - **SWD**: 200 mg once a day, taken approximately one hour prior to the start of their work shift. (2.2)

  - **Severe Hepatic Impairment**: reduce dose to half the recommended dose. (2.3, 12.3)

  - **Geriatric Patients**: consider lower dose. (2.4, 12.3)

**Dosage and Administration**

The recommended dosage of PROVIGIL for each indication is as follows:

- **Narcolepsy or OSA**: 200 mg once a day. (2.1)

- **SWD**: 200 mg once a day, taken approximately one hour prior to the start of their work shift. (2.2)

- **Severe Hepatic Impairment**: reduce dose to half the recommended dose. (2.3, 12.3)

- **Geriatric Patients**: consider lower dose. (2.4, 12.3)

DOSAGE FORMS AND STRENGTHS

Tablets: 100 mg and 200 mg. (3)

CONTRAINDICATIONS

PROVIGIL is contraindicated in patients with known hypersensitivity to modafinil or armodafinil. (4)
with fever and other abnormalities (e.g., vomiting, leukopenia). The median time to rash that resulted in discontinuation was 13 days. No such cases were observed among 380 pediatric patients who received placebo. PROVIGIL is not approved for use in pediatric patients for any indication [see Use in Specific Populations (8.4)].

Rare cases of serious or life-threatening rash, including SJS, Toxic Epidermal Necrolysis (TEN), and Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) have been reported in adults and children in worldwide postmarketing experience. The reporting rate of TEN and SJS associated with modafinil use, which is generally accepted to be an underestimate due to underreporting, exceeds the background incidence rate. Estimates of the background incidence rate for these serious skin reactions in the general population range between 1 to 2 cases per million-person years. There are no factors known to predict the risk of occurrence or the severity of rash associated with PROVIGIL. Nearly all cases of serious rash associated with modafinil occurred within 1 to 5 weeks after treatment initiation. However, isolated cases have been reported after prolonged treatment (e.g., 3 months). Accordingly, duration of therapy cannot be relied upon as a means to predict the potential risk heralded by the first appearance of a rash.

Although benign rashes also occur with PROVIGIL, it is not possible to reliably predict which rashes will prove to be serious. Accordingly, PROVIGIL should be discontinued at the first sign of rash, unless the rash is clearly not drug-related. Discontinuation of a multi-organ hypersensitivity reaction should prevent a rash from becoming life-threatening or permanently disabling or disfiguring.

5.2 Angioedema and Anaphylaxis Reactions

Angioedema and hypersensitivity (with rash, dysphagia, and bronchospasm), were observed in patients treated with modafinil, the R enantiomer of modafinil (which is the R-enantiomer of racemic modafinil). Serious events such as cases were observed in modafinil-treated patients. However, angioedema has been reported in postmarketing experience with modafinil. Patients should be advised to discontinue therapy and immediately report to their physician any signs or symptoms suggesting angioedema or anaphylaxis (e.g., swelling of face, eyes, lips, tongue or larynx; difficulty in swallowing or breathing; hoarseness).

5.3 Multi-organ Hypersensitivity Reactions

Multi-organ hypersensitivity reactions, including at least one fatality in postmarketing experience, have occurred in close temporal association (median time to detection 13 days: range 4-33) to the initiation of modafinil. Although there have been a limited number of reports, multi-organ hypersensitivity reactions (a frequency >0.3%) and reported more often in patients treated with PROVIGIL compared to those treated with placebo were anxiety (1%), nervousness (1%), insomnia (1%), confusion (1%), agitation (1%), and depression (1%). Postmarketing adverse reactions associated with the use of modafinil have included mania, delusions, hallucinations, suicidal ideation, and aggression, some resulting in hospitalization. Manic behavior, one healthy male volunteer developed ideas of reference, paranoid delusions, and auditory hallucinations in association with multiple daily 600 mg doses of PROVIGIL (three times the recommended dose) and sleep deprivation. There was no evidence of psychosis 36 hours after drug discontinuation. Caution should be exercised when PROVIGIL is given to patients with a history of psychosis, depression, or mania. Consideration should be given to the possible emergence or exacerbation of psychiatric symptoms in patients treated with PROVIGIL. If psychiatric symptoms develop in association with PROVIGIL administration, consider discontinuing PROVIGIL.

5.5 Psychiatric Symptoms

Psychiatric adverse reactions have been reported in patients treated with modafinil. In the adult PROVIGIL controlled trials, psychiatric symptoms resulting in treatment discontinuation (at a frequency >0.3%) and reported more often in patients treated with PROVIGIL compared to those treated with placebo were anxiety (1%), nervousness (1%), insomnia (1%), confusion (1%), agitation (1%), and depression (1%). Postmarketing adverse reactions associated with the use of modafinil have included mania, delusions, hallucinations, suicidal ideation, and aggression, some resulting in hospitalization. Manic behavior, one healthy male volunteer developed ideas of reference, paranoid delusions, and auditory hallucinations in association with multiple daily 600 mg doses of PROVIGIL (three times the recommended dose) and sleep deprivation. There was no evidence of psychosis 36 hours after drug discontinuation. Caution should be exercised when PROVIGIL is given to patients with a history of psychosis, depression, or mania. Consideration should be given to the possible emergence or exacerbation of psychiatric symptoms in patients treated with PROVIGIL. If psychiatric symptoms develop in association with PROVIGIL administration, consider discontinuing PROVIGIL.

5.6 Effects on Ability to Drive and Use Machinery

Although PROVIGIL has not been shown to produce functional impairment, any drug affecting the CNS may alter judgment, thinking or motor skills. Patients should be cautioned about operating an automobile or other hazardous machinery until it is reasonably certain that PROVIGIL therapy will not adversely affect their ability to engage in such activities.

5.7 Cardiovascular Events

In modafinil clinical studies, cardiovascular adverse reactions, including chest pain, palpitations, dyspnea, and transient ischemic T-wave changes on ECG occurred in three subjects in association with mitral valve prolapse or left ventricular hypertrophy. In a Canadian clinical trial, a 35-year-old obese narcoleptic male patient with a prior history of syncopal episodes experienced a 9-second episode of asystole after 27 days of modafinil treatment (300 mg/day in divided doses). PROVIGIL is not recommended in patients with a history of left ventricular hypertrophy or in patients with mitral valve prolapse who have experienced the mitral valve prolapse syndrome within the first 13 days: range 4-33) to the initiation of modafinil. However, angioedema has been reported in postmarketing experience with modafinil. Patients should be advised to discontinue therapy and immediately report to their physician any signs or symptoms suggesting angioedema or anaphylaxis (e.g., swelling of face, eyes, lips, tongue or larynx; difficulty in swallowing or breathing; hoarseness).

5.4 Persistent Sleepiness

Patients with abnormal levels of sleepiness who take PROVIGIL should be advised that their level of wakefulness may not return to normal. Patients with excessive sleepiness, including those taking PROVIGIL, should be frequently reassessed for their degree of sleepiness and, if appropriate, advised to avoid driving or any other potentially dangerous activity. Prescribers should also be aware that patients may not acknowledge sleepiness or drowsiness until directly questioned about drowsiness or sleepiness during specific activities.

6 ADVERSE REACTIONS

The following serious adverse reactions are described elsewhere in the labeling:

- Serious Rash, including Stevens-Johnson Syndrome [see Warnings and Precautions (5.1)]
- Angioedema and Anaphylaxis Reactions [see Warnings and Precautions (5.2)]
- Multi-organ Hypersensitivity Reactions [see Warnings and Precautions (5.3)]
- Persistent Sleepiness [see Warnings and Precautions (5.4)]
- Psychiatric Symptoms [see Warnings and Precautions (5.5)]
- Effects on Ability to Drive and Use Machinery [see Warnings and Precautions (5.6)]
- Cardiovascular Events [see Warnings and Precautions (5.7)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. PROVIGIL has been evaluated for safety in over 3,500 patients, of whom more than 2,000 patients with excessive sleepiness associated with OSA, SWD, and narcolepsy. Most Common Adverse Reactions

In placebo-controlled clinical trials, the most common adverse reactions (≥5%) associated with the use of PROVIGIL more frequently than placebo-treated patients were headache, nausea, nervousness, rhinitis, diarrhea, back pain, anxiety, insomnia, dizziness, and dyspnea. The adverse reaction profile was similar across these studies. Table 1 presents the adverse reactions that occurred at a rate of 1% or more and were more frequent in PROVIGIL-treated patients than in placebo-treated patients in the placebo-controlled clinical trials.

Table 1. Adverse Reactions in Pooled Placebo-Controlled Trials* in Narcolepsy, OSA, and SWD

<table>
<thead>
<tr>
<th>PROVIGIL (%) (n = 934)</th>
<th>Placebo (%) (n = 567)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>34</td>
</tr>
<tr>
<td>Nausea</td>
<td>11</td>
</tr>
<tr>
<td>Nervousness</td>
<td>7</td>
</tr>
<tr>
<td>Rhinitis</td>
<td>7</td>
</tr>
<tr>
<td>Back Pain</td>
<td>6</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>6</td>
</tr>
<tr>
<td>Anxiety</td>
<td>5</td>
</tr>
<tr>
<td>Dizziness</td>
<td>5</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>5</td>
</tr>
<tr>
<td>Insomnia</td>
<td>5</td>
</tr>
<tr>
<td>Anorexia</td>
<td>4</td>
</tr>
<tr>
<td>Dry Mouth</td>
<td>4</td>
</tr>
<tr>
<td>Pharyngitis</td>
<td>4</td>
</tr>
<tr>
<td>Chest Pain</td>
<td>3</td>
</tr>
<tr>
<td>Hypertension</td>
<td>3</td>
</tr>
<tr>
<td>Abnormal Liver Function</td>
<td>2</td>
</tr>
<tr>
<td>Constipation</td>
<td>2</td>
</tr>
<tr>
<td>Depression</td>
<td>2</td>
</tr>
<tr>
<td>Palpitation</td>
<td>2</td>
</tr>
<tr>
<td>Paresthesia</td>
<td>2</td>
</tr>
<tr>
<td>Somnolence</td>
<td>2</td>
</tr>
<tr>
<td>Tachycardia</td>
<td>2</td>
</tr>
<tr>
<td>Vasodilatation</td>
<td>2</td>
</tr>
<tr>
<td>Abnormal Vision</td>
<td>1</td>
</tr>
<tr>
<td>Hyperhidrosis</td>
<td>1</td>
</tr>
<tr>
<td>Asthma</td>
<td>1</td>
</tr>
<tr>
<td>Chills</td>
<td>1</td>
</tr>
</tbody>
</table>
PROVIGIL® (modafinil) Tablets [C-IV]

**Adverse Reactions that occurred in > 1% of PROVIGIL-treated patients (either 200, 300, or 400 mg once daily) and greater incidence than placebo**

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>PROVIGIL (%)</th>
<th>Placebo (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Confusion</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Dyskinesia</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Edema</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Emotional Lability</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Esosinophilia</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Epistaxis</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Flatulence</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Hyperkinesia</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Hypertonia</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Mouth Ulceration</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Sweating</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Taste Perversion</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Thirst</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Tremor</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Urine Abnormality</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Vertigo</td>
<td>1</td>
<td>0</td>
</tr>
</tbody>
</table>

*Dose-Dependent Adverse Reactions*

In the placebo-controlled clinical trials which compared doses of 200, 300, and 400 mg/day of PROVIGIL and placebo, the following adverse reactions were dose related: headache and anxiety.

**Adverse Reactions Resulting in Discontinuation of Treatment**

In placebo-controlled clinical trials, 74 of the 934 patients (8%) who received PROVIGIL discontinued due to adverse reactions compared to 3% of patients who received placebo. The most frequent reasons for discontinuation that occurred at a higher rate for PROVIGIL than placebo patients were headache (2%), nausea, anxiety, dizziness, insomnia, chest pain, and nervousness (each <1%).

**Laboratory Abnormalities**

Clinical chemistry, hematology, and urinalysis parameters were monitored in the studies. Mean plasma levels of gamma glutamyltransferase (GGT) and alkaline phosphatase (AP) were found to be higher following administration of PROVIGIL, but not placebo. Few patients, however, had GGT or AP elevations outside of the normal range. Shifts to higher, but not clinically significantly abnormal, GGT and AP values appeared to increase with time in the population treated with PROVIGIL in the placebo-controlled clinical trials. No differences were apparent in alanine aminotransferase (ALT), aspartate aminotransferase (AST), total protein, albumin, or total bilirubin.

**8.1 Pregnancy**

Pregnancy Category C

There are no adequate and well-controlled studies of modafinil in pregnant women. Intrauterine growth restriction and spontaneous abortion have been reported in association with modafinil (a mixture of R- and S-modafinil) and armodafinil (the R-enantiomer of modafinil). Although the pharmacokinetics of modafinil is not identical to that of the sympathomimetic amines, it does share some pharmacologic properties with this class. Certain of these drugs have been associated with intrauterine growth restriction and spontaneous abortions. Whether the cases reported with modafinil are drug-related is unknown. In studies of modafinil and armodafinil conducted in rats (modafinil, armodafinil) and rabbits (modafinil), developmental toxicity was observed at clinically relevant plasma exposures. PROVIGIL should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Modafinil (50, 100, or 200 mg/kg/day) administered orally to pregnant rats throughout organogenesis resulted in increased incidences of fetal visceral and skeletal variations and decreased fetal body weight at the highest dose tested. The highest no-effect dose for embryofetal development in rats (100 mg/kg/day) was associated with a plasma modafinil AUC less than that in humans at the recommended human dose (RHD) of PROVIGIL (200 mg/day). However, in a subsequent study of up to 480 mg/kg/day of modafinil, no adverse effects on embryofetal development were observed. Oral administration of armodafinil (60, 200, or 600 mg/kg/day) to pregnant rats throughout organogenesis resulted in increased incidences of fetal visceral and skeletal variations and decreased fetal body weight at the highest dose tested. The highest no-effect dose for embryofetal development (100 mg/kg/day) was associated with a plasma armodafinil AUC less than that in humans at the RHD of PROVIGIL.

Modafinil administered orally to pregnant rabbits throughout organogenesis at doses of up to 100 mg/kg/day had no effect on embryofetal development; however, the doses used were too low to adequately assess the effects of modafinil on embryofetal development. In a subsequent study, the highest dose of 450, 90, and 180 mg/kg/day in pregnant rabbits, the incidences of fetal structural alterations and embryofetal death were increased at the highest dose. The highest no-effect dose for developmental toxicity (100 mg/kg/day) was associated with a plasma modafinil AUC similar to that in humans at the RHD of PROVIGIL. Modafinil administered to rats throughout gestation and lactation at oral doses of up to 200 mg/kg/day resulted in decreased viability in the offspring at doses greater than 20 mg/kg/day, a dose resulting in a plasma modafinil AUC less than that in humans at the RHD of PROVIGIL. No effects on postnatal developmental and neurobehavioral parameters were observed in surviving offspring.

**Pregnancy Registry**

A pregnancy registry has been established to collect information on the pregnancy outcomes of women exposed to PROVIGIL. Healthcare providers are encouraged to register pregnant patients, or pregnant women may enroll themselves in the registry by calling 1-866-404-4105 (toll free).

**8.2 Nursing Mothers**

It is not known whether modafinil or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when PROVIGIL is administered to a nursing woman.

**8.4 Pediatric Use**

Safety and effectiveness in pediatric patients have not been established. PROVIGIL is not approved for use in treating ADHD.

**8.5 Geriatric Use**

In clinical trials, experience in a limited number of modafinil-treated patients who were greater than 65 years of age showed an incidence of adverse reactions similar to other age groups. In elderly patients, elimination of modafinil and its metabolites may be reduced as a consequence of aging. Therefore, consideration should be given to the use of lower doses and close monitoring in this population [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)].
8.6 Hepatic Impairment

In patients with severe hepatic impairment, the dose of PROVIGIL should be reduced to one-half of that recommended for patients with normal hepatic function [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)].

9 DRUG ABUSE AND DEPENDENCE

9.1 Controlled Substance

PROVIGIL contains modafinil, a Schedule IV controlled substance.

9.2 Abuse

In humans, modafinil produces psychoactive and euphoric effects, alterations in mood, perception, thinking, and feelings typical of other CNS stimulants. In in vitro binding studies, modafinil binds to the dopamine transporter in monkeys previously trained to self-administer cocaine. In some studies, modafinil was also partially discriminated as stimulant-like. Physicians should follow patients closely, especially those with a history of drug and/or stimulant (e.g., methylphenidate, amphetamine, or cocaine) abuse. Patients should be observed for signs of misuse or abuse (e.g., incrementation of doses or drug-seeking behavior).

The abuse potential of modafinil (200, 400, and 800 mg) was assessed relative to methylphenidate (45 and 90 mg) in an inpatient study in individuals experienced with drugs of abuse. Results from this clinical study demonstrated that modafinil produced psychoactive and euphoric effects and feelings consistent with other scheduled CNS stimulants (methylphenidate).

9.3 Dependence

In one placebo-controlled clinical trial, the effects of modafinil withdrawal were monitored following 9 weeks of modafinil use. There were no reported withdrawal symptoms with modafinil during 14 days of observation, although sleepiness returned in narcoleptic patients.

10 OVERDOSAGE

In clinical trials, a total of 151 protocol-specified doses ranging from 1000 to 1600 mg/day (5 to 8 times the recommended daily dose of PROVIGIL) have been administered to 32 subjects, including 13 subjects who received doses of 1000 or 1200 mg/day for 7 to 21 consecutive days. In addition, several intentional acute overdoses occurred; the two largest being 4500 mg and 4000 mg taken by two subjects participating in foreign depression studies. None of these study subjects experienced any unexpected or life-threatening effects. Adverse reactions that were reported at these doses included excitation or agitation, insomnia, and slight or moderate elevations in hemodynamic parameters. Other observed high-dose effects in clinical studies have included anxiety, irritability, aggressiveness, confusion, nervousness, tremor, palpitations, sleep disturbances, nausea, diarrhea, and decreased prothrombin time.

From postmarketing experience, there have been reports of fatal overdoses involving modafinil alone or in combination with other drugs. Symptoms most often accompanying PROVIGIL overdose, alone or in combination with other drugs have included insomnia; central nervous system symptoms such as restlessness, disinhibition, confusion, agitation, anxiety, excitation, and hallucination; digestive changes such as nausea and diarrhea; and cardiovascular changes such as tachycardia, bradycardia, hypertension, and chest pain.

Cases of accidental ingestion overdose have been reported in children as young as 11 months of age. The highest reported accidental ingestion on a mg/kg basis occurred in a three-year-old boy who ingested 800-1000 mg (50-63 mg/kg) of PROVIGIL. The child remained stable. The symptoms associated with overdose in children were similar to those observed in adults.

No specific antidote exists for the toxic effects of a PROVIGIL overdose. Such overdoses should be managed with primary supportive care, including cardiovascular monitoring.

11 DESCRIPTION

PROVIGIL (modafinil) is a wakefulness-promoting agent for oral administration. Modafinil is a racemic compound. The chemical name for modafinil is 2-[(diphenylmethyl)sulfonyl]acetamide. The molecular formula is C23H19NO6S and the molecular weight is 427.35.

The chemical structure is:

[Chemical structure image]

Modafinil is a white to off-white, crystalline powder that is practically insoluble in water and cyclohexane. It is sparingly to slightly soluble in methanol and acetone. PROVIGIL tablets contain 100 mg or 200 mg of modafinil and the following inactive ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, and pregelatinized starch.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The mechanism(s) through which modafinil promotes wakefulness is unknown. Modafinil has wake-promoting actions similar to sympathomimetic agents including amphetamine and methylphenidate, although the pharmacologic profile is not identical to that of the sympathomimetic amines.

Modafinil-induced wakefulness cannot be attenuated by the α1-adrenergic receptor antagonist, prazosin; however, modafinil is inactive in other in vitro assay systems known to be responsive to α-adrenergic agonists such as the rat vas deferens preparation.

Modafinil is not a direct- or indirect-acting dopamine receptor agonist. However, in vitro, modafinil binds to the dopamine transporter and inhibits dopamine reuptake. This activity has been observed in vivo with increased extracellular dopamine levels in some brain regions of animals. In genetically engineered mice lacking the dopamine transporter (DAT), modafinil lacked wake-promoting activity, suggesting that this activity was DAT-dependent. However, the wake-promoting effects of modafinil, unlike those of amphetamine, were not antagonized by the dopamine receptor antagonist haloperidol in rats. In addition, alpha-methyl-p-tyrosine, a dopamine synthesis inhibitor, blocks the action of amphetamine, but does not block locomotor activity induced by modafinil.

In the cat, equal wakefulness-promoting doses of methylphenidate and amphetamine increased neuronal activation throughout the brain. Modafinil at an equivalent wakefulness-promoting dose selectively and prominently increased neuronal activation in more discrete regions of the brain. The relationship of this finding in cats to the effects of modafinil in humans is unknown.

In addition to its wake-promoting effects and ability to increase locomotor activity in the modafinil produces psychoactive and euphoric effects, alterations in mood, perception, thinking, and feelings typical of other CNS stimulants in humans. Modafinil has reinforcing properties, as evidenced by its self-administration in monkeys previously trained to self-administer cocaine; modafinil was also partially discriminated as stimulant-like.

The optical enantiomers of modafinil have similar pharmacological actions in animals. Two major metabolites of modafinil, modafinil acid and modafinil sulfone, do not appear to contribute to the CNS-activating properties of modafinil.

12.3 Pharmacokinetics

Modafinil is a racemic compound whose enantiomers have different pharmacokinetics (e.g., the half-life of R-modafinil is approximately three times that of S-modafinil in adult humans). The enantiomers do not interconvert. At steady state, total exposure to R-modafinil is approximately three times that for S-modafinil. The trough concentration (Ctmax) of circulating modafinil after once daily dosing consists of 10% of R-modafinil and 90% of S-modafinil. The elimination half-life of modafinil after multiple doses is about 15 hours. The enantiomers of modafinil exhibit linear kinetics upon multiple dosing of 200-600 mg/day once daily in healthy volunteers. Apparent steady states of total modafinil and R-modafinil are reached after 2-4 days of dosing.

Absorption

PROVIGIL is readily absorbed after oral administration, with peak plasma concentrations occurring at 2-4 hours. The bioavailability of PROVIGIL tablets is approximately equal to that of an aqueous suspension. The absolute oral bioavailability was not determined due to the aqueous insolubility (<1 mg/mL) of modafinil, which precludes oral administration. Food has no effect on overall PROVIGIL bioavailability; however, time to reach peak concentration (Ctmax) may be delayed by approximately one hour if taken with food.

Distribution

PROVIGIL has an apparent volume of distribution of approximately 0.9 L/kg. In human plasma, in vitro, modafinil is moderately bound to plasma protein (approximately 60%), mainly to albumin. The potential for interactions of PROVIGIL with highly protein-bound drugs is considered to be minimal.

Metabolism and Elimination

The major route of elimination is metabolism (approximately 90%), primarily by the liver. Subsequent renal elimination of the metabolites. Urine alkalization has no effect on the elimination of modafinil.

Metabolism occurs through hydrolytic deamination, S-oxidation, aromatic ring hydroxylation, and glucuronide conjugation. Less than 10% of an administered dose is recovered as the parent compound. In a clinical study using radiolabeled modafinil, the total amount of radioactivity excreted in the urine was 96% of the administered radioactivity was recovered in 11 days post-dose, predominantly in the urine (80% vs. 1.0% in the feces). The largest fraction of the drug in urine was modafinil acid, but at least six other metabolites were present in lower concentrations. Only two metabolites reach appreciable concentrations in plasma, i.e., modafinil acid and modafinil sulfone. In preclinical models, modafinil acid, modafinil sulfone, [2-(diphenylmethyl)sulfonyl]acetic acid and 4-hydroxy modafinil, were inactive or did not appear to mediate the arousing effects of modafinil.

In adults, decreases in trough levels of modafinil have sometimes been observed after multiple weeks of dosing, suggesting auto-induction, but the magnitude of the decrease and the inconsistency of their occurrence suggest that clinical significance is minimal. Significant accumulation of modafinil sulfone has been observed after multiple doses due to its long elimination half-life of 40 hours. Auto-induction of metabolizing enzymes, most importantly cytochrome P-450 CYF344, has also been observed in vitro after incubation of primary cultures of human hepatocytes and in vivo after extended administration of modafinil at 400 mg/day.

Specific Populations

Age

A slight decrease (approximately 20%) in the oral clearance (CL/F) of modafinil was observed in a single dose study at 200 mg in 12 subjects with a mean age of 63 years (range 53 – 72 years), but the change was considered not likely to be clinically significant. In a multiple dose study (300 mg/day) in 12 patients with a mean age of 82 years (range 67 – 87 years), the mean levels of modafinil in plasma were approximately two times those historically obtained in matched younger subjects.

Due to potential effects from the multiple concomitant medications with which most of the changes were being brought to the clinic, the changes were not considered to be clinically significant.
PROVIGIL® (modafinil) Tablets [C-IV]

Gender
The pharmacokinetics of modafinil are not affected by gender.

Race
The influence of race on the pharmacokinetics of modafinil has not been studied.

Renal Impairment
In a single dose 200 mg modafinil study, severe chronic renal failure (creatinine clearance <20 mL/min) did not significantly influence the pharmacokinetics of modafinil, but exposure to modafinil acid (an inactive metabolite) was increased 9-fold.

Hepatic Impairment
The pharmacokinetics and metabolism of modafinil were examined in patients with cirrhosis of the liver (6 men and 3 women). Three patients had stage B or C cirrhosis and 6 patients had stage C or C+ cirrhosis (per the Child-Pugh score criteria). Clinically 8 of 9 patients were icteric and all had ascites. In these patients, the oral clearance of modafinil was decreased by about 60% and the steady state concentration was doubled compared to normal patients [see Dosage and Administration (2.3) and Use in Specific Populations (8.6)].

Drug Interactions

In vitro data demonstrated that modafinil weakly induces CYP1A2, CYP2B6, and possibly CYP3A activities in a concentration-related manner and that CYP2C19 activity produced an apparent concentration-related suppression of expression of CYP2C9 activity. Other CYP activities did not appear to be affected by modafinil.

Potential Interactions with Drugs That Inhibit, Induce, or Are Metabolized by Cytochrome P450 Isoenzymes and Other Hepatic Enzymes

The existence of multiple pathways for modafinil metabolism, as well as the fact that a non-CYP-related pathway is the most rapid in metabolizing modafinil, suggest that there is a low probability of substantive effects on the overall pharmacokinetic profile of PROVIGIL due to CYP inhibition by concomitant medications. However, due to the partial involvement of CYP3A enzymes in the metabolic elimination of modafinil, coadministration of potent inducers of CYP3A4/5 (e.g., carbamazepine, phenytoin, rifampin) or inhibitors of CYP3A4 (e.g., ketoconazole, erythromycin, cilnidip) could alter the plasma concentrations of modafinil.

The Potential of PROVIGIL to Alter the Metabolism of Other Drugs by Enzyme Induction or Inhibition

- **Drugs Metabolized by CYP3A4/5**
  - In vitro data demonstrated that modafinil is a weak inducer of CYP3A activity in a concentration-related manner. Therefore, the blood levels and effectiveness of drugs that are substrates for CYP3A enzymes (e.g., steroidal contraceptives, cyclosporine, midazolam, and triazolam) may be reduced after initiation of concomitant treatment with PROVIGIL [see Drug Interactions (7)].

- **Ethinyl Estradiol** - Administration of modafinil to female volunteers once daily at 200 mg/day for 7 days followed by 400 mg/day for 21 days resulted in a mean 11% decrease in mean Cmax and 18% decrease in mean AUC0-24 of ethinyl estradiol (EE2: 0.035 mg; administered orally with norgestomet). There was no apparent change in the elimination rate of ethinyl estradiol.

- **Triazolam** - In the drug interaction study between PROVIGIL and ethinyl estradiol (EE), on the same days as those for the plasma sampling for EE, pharmacokinetics, a single dose of triazolam (0.125 mg) was also administered. Mean Cmax and AUC0-24 of triazolam were decreased by 42% and 59%, respectively, and its elimination half-life was decreased by approximately an hour after a modafinil treatment.

- **Cyclosporine** - One case of an interaction between modafinil and cyclosporine, a substrate of CYP3A4, has been reported in a 41 year old woman who had undergone an organ transplant. After one month of administration of 200 mg/day of modafinil, cyclosporine blood levels were decreased by 50%. The interaction was modulated to be due to the increased metabolism of cyclosporine, since no other factor expected to affect the disposition of the drug had changed.

- **Midazolam** - In a clinical study, concomitant administration of armodafinil 250 mg resulted in a reduction in systemic exposure to midazolam by 32% prior to a concurrent dose of 5 mg and 17% after a single intravenous dose (2 mg).

- **Quetiapine** - In a separate clinical study, concomitant administration of armodafinil 250 mg with quetiapine (300 mg to 600 mg daily doses) resulted in a reduction in the mean systemic exposure of quetiapine by approximately 29%.

- **Drugs Metabolized by CYP1A2**
  - In vitro data demonstrated that modafinil is a weak inducer of CYP1A2 in a concentration-related manner. However, in a clinical study with armodafinil using caffeine as a probe substrate, no significant effect on CYP1A2 activity was observed.

- **Drugs Metabolized by CYP2B6**
  - In vitro data demonstrated that modafinil is a weak inducer of CYP2B6 activity in a concentration-related manner.

- **Drugs Metabolized by CYP2C9**
  - In vitro data demonstrated that modafinil produced an apparent concentration-related suppression of expression of CYP2C9 activity suggesting that there is a potential for a metabolic interaction between modafinil and the substrates of this enzyme (e.g., S-warfarin and phenytoin) [see Drug Interactions (7)].

- **Warfarin** - Concomitant administration of modafinil with warfarin did not produce significant changes in the pharmacokinetic profiles of R- and S-warfarin. However, since only a single dose of warfarin was tested in this study, an interaction cannot be ruled out [see Drug Interactions (7)].

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

Carcinogenicity studies were conducted in which modafinil (a mixture of R- and S-modafinil) was administered in the diet to mice for 78 weeks and to rats for 104 weeks at doses of 6, 30, and 60 mg/kg/day. The highest doses studied were associated with plasma modafinil exposures (AUC) that were less than in humans at the recommended human dose (RHD) of PROVIGIL (200 mg/day). There was no evidence of tumorigenesis associated with modafinil administration in these studies. However, the mouse study was inadequate because the high dose was not a maximum tolerated dose (MTD). In a mouse carcinogenicity study in which armodafinil (the R-enantiomer of modafinil) was administered at oral doses of up to 300 mg/kg/day in males and 100 mg/kg/day in females for approximately 2 years, no tumorigenic effects were observed. The highest doses studied, which were considered MTDs, were associated with plasma armodafinil exposures less than (2 females) or 2 times (males) that in humans at the RHD of PROVIGIL.

Mutagenesis

Modafinil was negative in a series of in vitro (i.e., bacterial reverse mutation, mouse lymphoma tk, chromosomal aberration in human lymphocytes, cell transformation in BALB/3T3 mouse embryo cells) or in vivo (mouse bone marrow micronucleus) assays.

Impairment of Fertility

Oral administration of modafinil (doses of up to 480 mg/kg/day) to male and female rats prior to and throughout mating, and continuing in females through day 7 of gestation produced an increase in the time to mate at the highest dose; no effects were observed on other fertility or reproductive parameters. The no-effect dose of 240 mg/kg/day was associated with a plasma modafinil AUC less than that in humans at the RHD of PROVIGIL.

14 CLINICAL STUDIES

14.1 Narcolepsy

The effectiveness of PROVIGIL in improving wakefulness in adult patients with excessive sleepiness associated with narcolepsy was established in two US 9-week, multi-center, placebo-controlled, parallel-group, double-blind studies of outpatients who met the criteria for narcolepsy. A total of 558 patients were randomized to receive PROVIGIL 200 or 400 mg/day, or placebo. The criteria for narcolepsy include either: 1) recurrent daytime naps or lapses to sleep that occur almost daily for at least three months, plus sudden bilateral loss of postural muscle tone in association with sleep attacks (cataplexy), or 2) a complaint of excessive sleepiness or sudden muscle weakness associated with associated features: sleep paralysis, hypnagogic hallucinations, automatic behaviors, disrupted major sleep episode; and polysomnography demonstrating one of the following: sleep latency less than 10 minutes or rapid eye movement (REM) sleep latency less than 20 minutes. For entry into these studies, all patients were required to have objectively documented excessive daytime sleepiness, via a Multiple Sleep Latency Test (MSLT) with two or more sleep onset REM periods and the absence of any other clinically significant active medical or psychiatric disorder. The MSLT, an objective polysomnographic assessment of the patient’s ability to fall asleep in an unstimulating environment, measured latency (in minutes) to sleep
onset averaged over 4 test sessions at 2-hour intervals. For each test session, the subject was told to go to bed at his or her normal bedtime and attempt to sleep. Each test session was terminated after 20 minutes if no sleep occurred or 15 minutes after sleep onset.

In both studies, the primary measures of effectiveness were: 1) sleep latency, as assessed by the Maintenance of Wakefulness Test (MWT); and 2) the change in the patient’s overall disease status, as measured by the Clinical Global Impression of Change (CGI-C). For a successful trial, both measures had to show statistically significant improvement.

The MWT measures latency (in minutes) to sleep onset averaged over 4 test sessions at 2 hour intervals following nocturnal polysomnography. For each test session, the subject was asked to attempt to remain awake without using extraordinary measures. Each test session was terminated after 20 minutes if no sleep occurred or 10 minutes after sleep onset. The CGI-C is a 7-point scale, centered at No Change, and ranging from Very Much Worse to Very Much Improved. Patients were rated by evaluators who had no access to any data about the patients other than a measure of their baseline severity. Evaluators were not given any specific guidance about the criteria that were to apply when rating patients.

Both studies demonstrated improvement in objective and subjective measures of excessive daytime sleepiness for both the 200 mg and 400 mg doses compared to placebo. Patients treated with PROVIGIL showed a statistically significantly enhanced ability to remain awake on the MWT at each dose compared to placebo at final visit (Table 2). A statistically significantly greater number of patients treated with PROVIGIL at each dose showed improvement in overall clinical condition as rated by the CGI-C scale at final visit (Table 3).

Nighttime sleep measured with polysomnography was not affected by the use of PROVIGIL.

14.2 Obstructive Sleep Apnea (OSA)

The effectiveness of PROVIGIL in improving wakefulness in patients with excessive sleepiness associated with OSA was established in two multi-center, placebo-controlled clinical studies of patients who met the criteria for OSA. The criteria include a history of excessive sleepiness or insomnia, plus frequent episodes of impaired breathing during sleep, and associated features such as loud snoring, morning headaches and dry mouth upon awakening; or 2) excessive sleepiness or insomnia and polysomnography demonstrating one of the following: more than five obstructive apneas, each greater than 10 seconds in duration, per hour of sleep on one or both nights; or frequent arousals from sleep associated with the apneas, bradycardia, and arterial oxygen desaturation in association with the apneas. In addition, for entry into these studies, all patients were required to have excessive sleepiness as demonstrated by a score >10 on the Epworth Sleepiness Scale (ESS), despite treatment with continuous positive airway pressure (CPAP).

Evidence that CPAP was effective in reducing episodes of apnea/hypopnea was required along with documentation of CPAP use.

In the first study, a 12-week trial, a total of 327 patients with OSA were randomized to receive PROVIGIL 200 mg/day, PROVIGIL 400 mg/day, or matching placebo. The major inclusion criteria were: 1) patients with apneas, bradycardia, and arterial oxygen desaturation in association with the apneas; and 2) the patient’s overall disease status, as measured by the Clinical Global Impression of Change (CGI-C) at the final visit [see Clinical Studies (14.1) for a description of these measures].

Patients treated with PROVIGIL showed a statistically significant improvement in the ability to remain awake compared to placebo-treated patients as measured by the MWT (Table 2). A statistically significantly greater number of patients treated with PROVIGIL showed improvement in overall clinical condition as rated by the CGI-C scale at final visit (Table 3). The 200 mg and 400 mg doses of PROVIGIL produced statistically significantly better effects of similar magnitude on the MWT, and also on the CGI-C.

In the second study, a 4-week trial, 157 patients with OSA were randomized to receive PROVIGIL 400 mg/day or placebo. Documentation of regular CPAP use (at least 4 hours/night on >70% of nights) was required for all patients. The primary measure of effectiveness was the change from baseline on the ESS at final visit. The baseline ESS scores for the PROVIGIL and placebo groups were 14.2 and 14.4, respectively. At week 4, improved by 4.6 in the PROVIGIL group and by 2.0 in the placebo group, a difference that was statistically significant.

Nighttime sleep measured with polysomnography was not affected by the use of PROVIGIL.

14.3 Shift Work Disorder (SWD)

The effectiveness of PROVIGIL in improving wakefulness in patients with excessive sleepiness associated with SWD was demonstrated in a 12-week placebo-controlled clinical trial. A total of 209 patients with chronic SWD were randomized to receive PROVIGIL 200 mg/day or placebo. All patients met the criteria for chronic SWD. The criteria include: 1) either, a) a primary complaint of excessive sleepiness or insomnia which is associated with a work shift change (e.g. time zone change [jet lag] syndrome); or b) no other medical or mental disorder accounts for the symptoms, and 3) the symptoms do not meet criteria for any other sleep disorder producing insomnia or excessive sleepiness (e.g. time zone change [jet lag] syndrome).

It should be noted that not all patients with a complaint of sleepiness who are also engaged in shift work meet the criteria for the diagnosis of SWD. In the clinical trial, only patients who were symptomatic for at least 3 months were enrolled.

Enrolled patients were also required to work a minimum of 5 night shifts per month, have excessive sleepiness at the time of their night shifts (MSLT score < 6 minutes), and have daytime insomnia documented by a daytime polysomnogram.

The primary measures of effectiveness were 1) sleep latency, as assessed by the MSLT performed during a simulated night shift at the final visit and 2) the change in the patient’s overall disease status, as measured by the CGI-C at the final visit [see Clinical Studies (14.1) for a description of these measures].

Patients treated with PROVIGIL showed a statistically significant prolongation in the time to sleep onset compared to placebo-treated patients, as measured by the nighttime MSLT at final visit (Table 2). A statistically significantly greater number of patients treated with PROVIGIL showed improvement in overall clinical condition as rated by the CGI-C scale at final visit (Table 3).

Daytime sleep measured with polysomnography was not affected by the use of PROVIGIL.

Table 2. Average Baseline Sleep Latency and Change from Baseline at Final Visit (MWT and MSLT in minutes)

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Measure</th>
<th>PROVIGIL Baseline</th>
<th>Change from Baseline</th>
<th>PROVIGIL Baseline</th>
<th>Change from Baseline</th>
<th>PROVIGIL Baseline</th>
<th>Change from Baseline</th>
<th>Placebo Baseline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Narcolepsy</td>
<td>MWT</td>
<td>5.8</td>
<td>2.3</td>
<td>6.6</td>
<td>2.3</td>
<td>5.8</td>
<td>-0.7</td>
<td>5.9</td>
</tr>
<tr>
<td>Narcolepsy</td>
<td>MSLT</td>
<td>6.1</td>
<td>2.2</td>
<td>5.9</td>
<td>2.0</td>
<td>6.0</td>
<td>-0.7</td>
<td>6.7</td>
</tr>
<tr>
<td>OSA</td>
<td>MWT</td>
<td>13.1</td>
<td>1.6</td>
<td>13.6</td>
<td>1.5</td>
<td>13.8</td>
<td>-1.1</td>
<td>14.9</td>
</tr>
<tr>
<td>SWD</td>
<td>MSLT</td>
<td>2.1</td>
<td>1.7</td>
<td>-</td>
<td>-</td>
<td>2.0</td>
<td>0.3</td>
<td>-</td>
</tr>
</tbody>
</table>

* Significantly different than placebo for all trials (p<0.01 for all trials but SWD, which was p<0.05).

16 HOW SUPPLIED/STORAGE AND HANDLING

PROVIGIL® (modafinil) tablets are available as follows: 100 mg: Each capsule-shaped, white to off white tablet is debossed with “PROVIGIL” on one side and “100 MG” on the other. NDC 63459-101-30 – Bottles of 30
200 mg: Each capsule-shaped, white to off white, scored tablet is debossed with “PROVIGIL” on one side and “200 MG” on the other. NDC 63459-201-30 – Bottles of 30

16.2 Storage
Store at 20° to 25°C (68° to 77°F).

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Allergic Reactions
Advise patients to stop taking PROVIGIL and to notify their physician right away if they develop a rash, hives, mouth sores, blisters, peeling skin, trouble swallowing or breathing, or a related allergic phenomenon.

Driving and Dangerous Activities
Advise patients not to alter their previous behavior with regard to potentially dangerous activities (e.g., driving, operating machinery) or other activities requiring appropriate levels of wakefulness until and unless treatment with PROVIGIL has been shown to produce levels of wakefulness that permit such activities. Advise patients that PROVIGIL is not a replacement for sleep.

Continuing Previously Prescribed Treatments
Inform patients that it may be critical that they continue to take their previously prescribed treatments (e.g., patients with OSA receiving CPAP should continue to do so).

Discontinuing Drug Due to Adverse Reactions
Advise patients not to discontinue PROVIGIL and contact their physician right away if they experience chest pain, rash, depression, anxiety, or signs of psychosis or mania.

Pregnancy
Advise patients to notify their physician if they become pregnant or intend to become pregnant during therapy. Caution patients regarding the potential increased risk of pregnancy when using steroidal contraceptives (including depot or implantable contraceptives) with PROVIGIL and for one month after discontinuation of therapy.

Informed Consent
Advise patients to notify their physician if they are breastfeeding an infant.

Concomitant Medication
Advise patients to inform their physician if they are taking, or plan to take, any prescription or over-the-counter drugs, because of the potential for interactions between PROVIGIL and other drugs.
MEDICATION GUIDE

PROVIGIL® (modafinil) Tablets [C-IV]

Read this Medication Guide before you start taking PROVIGIL and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or treatment.

What is the most important information I should know about PROVIGIL?

PROVIGIL® may cause serious side effects including a serious rash or a serious allergic reaction that may affect parts of your body such as your liver or blood cells. Any of these may need to be treated in a hospital and may be life-threatening.

Stop taking PROVIGIL and call your doctor right away if you have any of these symptoms:
- skin rash, hives, sores in your mouth, or your skin blisters and peels
- swelling of your face, eyes, lips, tongue, or throat
- trouble swallowing or breathing
- fever, shortness of breath, swelling of the legs, yellowing of the skin or whites of the eyes, or dark urine

If you have a severe rash with PROVIGIL, stopping the medicine may not keep the rash from becoming life-threatening or causing you to be permanently disabled or disfigured.

PROVIGIL® is not approved for use in children for any medical condition.

It is not known if PROVIGIL is safe or effective in children under 17 years of age.

What is PROVIGIL®?

PROVIGIL® is a prescription medicine used to improve wakefulness in adults who are very sleepy due to one of the following diagnosed sleep disorders:
- narcolepsy
- obstructive sleep apnea (OSA). PROVIGIL® is used to treat excessive sleepiness, but not the obstruction or medical condition that is causing OSA. You should talk with your doctor about treatments for OSA before you start taking PROVIGIL® and during treatment with PROVIGIL®. PROVIGIL® does not take the place of treatments that your doctor has prescribed for OSA. It is important that you continue to use these treatments as prescribed by your doctor.
- shift work disorder (SWD)

PROVIGIL® will not cure these sleep disorders. PROVIGIL® may help the sleepiness caused by these conditions, but it may not stop all your sleepiness. PROVIGIL® does not take the place of getting enough sleep. Follow your doctor’s advice about good sleep habits and using other treatments.

PROVIGIL® is a federally controlled substance (C-IV) because it can be abused or lead to dependence. Keep PROVIGIL® in a safe place to prevent misuse and abuse. Selling or giving away PROVIGIL® may harm others, and is against the law. Tell your doctor if you have ever abused or been dependent on alcohol, prescription medicines, or street drugs.

Who should not take PROVIGIL®?

Do not take PROVIGIL® if you:
- are allergic or developed a rash to modafinil or armodafinil (NUVIGIL®) or any of the ingredients in PROVIGIL®. See the end of this Medication Guide for a complete list of ingredients in PROVIGIL®.

What should I tell my doctor before taking PROVIGIL®?

Tell your doctor about all of your medical conditions including, if you:
- have a history of mental health problems, including psychosis
- have heart problems or had a heart attack
- have high blood pressure. Your blood pressure may need to be checked more often while taking PROVIGIL®.
- have liver or kidney problems
- have a history of drug or alcohol abuse or addiction
- are pregnant or planning to become pregnant. It is not known if PROVIGIL® will harm your unborn baby.

Pregnancy Registry: There is a registry for women who become pregnant during treatment with PROVIGIL®. The purpose of this registry is to collect information about the safety of PROVIGIL® during pregnancy. Contact the registry as soon as you learn that you are pregnant, or ask your doctor to contact the registry for you. You or your doctor can get information and enroll you in the registry by calling 1-866-404-4106.
- are breastfeeding. It is not known if PROVIGIL® passes into your breast milk. Talk to your doctor about the best way to feed your baby if you take PROVIGIL®.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. PROVIGIL® and many other medicines can interact with each other, sometimes causing side effects. PROVIGIL® may affect the way other medicines work, and other medicines may affect how PROVIGIL® works. Your dose of PROVIGIL® or certain other medicines may need to be changed.

Especially, tell your doctor if you use or take:
- a hormonal birth control method, such as birth control pills, shots, implants, patches, vaginal rings, and intrauterine devices (IUDs). Hormonal birth control methods may not work while you take PROVIGIL®. Women who use one of these methods of birth control may have a higher chance for getting pregnant while taking PROVIGIL®, and for one month after stopping PROVIGIL®. Talk to your doctor about birth control choices that are right for you while taking PROVIGIL®.

Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist when you get a new medicine. Your doctor or pharmacist will tell you if it is safe to take PROVIGIL® and other medicines together. Do not start any new medicines with PROVIGIL® unless your doctor has told you it is okay.

How should I take PROVIGIL®?

Take PROVIGIL® exactly as prescribed by your doctor. Your doctor will prescribe the dose of PROVIGIL® that is right for you. Do not change your dose of PROVIGIL® without talking to your doctor.
- Your doctor will tell you the right time of day to take PROVIGIL®.
  - People with narcolepsy or OSA usually take PROVIGIL® 1 time each day in the morning.
  - People with SWD usually take PROVIGIL® about 1 hour before their work shift.
- Do not change the time of day you take PROVIGIL® unless you have talked to your doctor. If you take PROVIGIL® too close to your bedtime, you may find it harder to go to sleep.
- You can take PROVIGIL® with or without food.
- If you take more than your prescribed dose or if you take an overdose of PROVIGIL®, call your doctor or go to the nearest hospital emergency room right away.

Symptoms of an overdose of PROVIGIL® may include:
- trouble sleeping
- restlessness
confusion
feeling disoriented
feeling excited
hearing, seeing, feeling, or sensing things that are not really there (hallucinations)
nausea and diarrhea
a fast or slow heartbeat
chest pain
increased blood pressure

What should I avoid while taking PROVIGIL?
• Do not drive a car or do other dangerous activities until you know how PROVIGIL affects you. People with sleep disorders should always be careful about doing things that could be dangerous. Do not change your daily habits until your doctor tells you it is okay.
• You should avoid drinking alcohol. It is not known how drinking alcohol will affect you when taking PROVIGIL.

What are possible side effects of PROVIGIL?
PROVIGIL may cause serious side effects. Stop taking PROVIGIL and call your doctor right away or get emergency help if you get any of the following:
• a serious rash or serious allergic reaction. (See “What is the most important information I should know about PROVIGIL?”)
• mental (psychiatric) symptoms, including:
  • depression
  • feeling anxious
  • hearing, seeing, feeling, or sensing things that are not really there (hallucinations)
  • an extreme increase in activity and talking (mania)
  • thoughts of suicide
  • aggressive behavior
  • other mental problems
• symptoms of a heart problem, including chest pain, abnormal heartbeat, and trouble breathing.
Common side effects that can happen in anyone who takes PROVIGIL include:
• headache
• back pain
• nausea
• feeling nervous
• stuffy nose
• diarrhea
• feeling anxious
• trouble sleeping
• dizziness
• upset stomach

PROVIGIL is not approved for use in children for any medical condition including Attention Deficit Hyperactivity Disorder (ADHD). In studies of PROVIGIL in children with narcolepsy, side effects included:
• Tourette's syndrome
• hostile behavior
• increase in sudden loss of muscle tone and severe muscle weakness
• increase in seeing and hearing things when falling asleep
• increase in suicidal thoughts
• low white blood count
• painful menstrual periods

Tell your doctor if you get any side effect that bothers you or that does not go away while taking PROVIGIL.
These are not all the side effects of PROVIGIL. For more information, ask your doctor or pharmacist.
Some effects of PROVIGIL on the brain are the same as other medicines called “stimulants”. These effects may lead to abuse or dependence on PROVIGIL.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.